La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George Tidmarsh purchased 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $9.53 per share, for a total transaction of $76,240.00. Following the completion of the purchase, the chief executive officer now directly owns 1,391,086 shares in the company, valued at approximately $13,257,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
LJPC has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of La Jolla Pharmaceutical Company from $32.00 to $33.00 in a research note on Monday, April 7th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Finally, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock.
Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 9.09 on Wednesday. La Jolla Pharmaceutical Company has a 52-week low of $0.16 and a 52-week high of $19.50. The stock has a 50-day moving average of $11.00 and a 200-day moving average of $8.86. The company’s market cap is $66.0 million.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.17. On average, analysts predict that La Jolla Pharmaceutical Company will post $-2.82 earnings per share for the current fiscal year.
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.